The science behind the 7th edition Tumour, Node, Metastasis staging system for lung cancer

Respirology

Volumn 17, Issue 2, 2012, Pages 247-260

  Marshall, Henry M ^a,b   Leong, Steven C ^a,b   Bowman, Rayleen V ^a,b   Yang, Ian A ^a,b   Fong, Kwun M ^a,b  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

International Association for the Study of Lung Cancer; lung cancer staging; staging revisions; staging validity; TNM classification

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CLASSIFICATION; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARCINOID; HISTOPATHOLOGY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PLEURA DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SMALL CELL CARCINOMA; TUMOR VOLUME;

HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS;

EID: 84856243795     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02083.x     Document Type: Review

References (60)

1. Gospodarowicz M, Miller D, Groome P, et al,. The process for continuous improvement of the TNM Classification. Cancer 2004; 100: 1-5. (Pubitemid 37553532)
2. Sobin L, Gospodarowicz M, Wittekind C, (eds). TNM Classification of Malignant Tumours, 7th edn. Wiley-Blackwell, Chichester, 2009.
3. Mountain C, Carr D, Anderson W,. A system for the clinical staging of lung cancer. AJR Am. J. Roentgenol. 1974; 120: 130-38.
4. Mountain CF,. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-7. (Pubitemid 27260107)
5. Goldstraw P,. Report on the international workshop on intrathoracic staging, London, October 1996. Lung Cancer 1997; 18: 107-11.
6. Goldstraw P, Crowley J, Chansky K, et al,. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J. Thora. Oncol. 2007; 2: 706-14. (Pubitemid 47357522)
7. Groome PA, Bolejack V, Crowley JJ, et al,. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J. Thora. Oncol. 2007; 2: 694-705. (Pubitemid 47357521)
8. Postmus PE, Brambilla E, Chansky K, et al,. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J. Thora. Oncol. 2007; 2: 686-93. (Pubitemid 47357520)
9. Rami-Porta R, Ball D, Crowley J, et al,. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J. Thora. Oncol. 2007; 2: 593-602. (Pubitemid 47171780)
10. Rusch VW, Crowley J, Giroux DJ, et al,. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J. Thora. Oncol. 2007; 2: 603-12. (Pubitemid 47171781)
11. Shepherd FA, Crowley J, Van Houtte P, et al,. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J. Thora. Oncol. 2007; 2: 1067-77. (Pubitemid 350307898)
12. Vallieres E, Shepherd FA, Crowley J, et al,. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J. Thora. Oncol. 2009; 4: 1049-59.
13. Surveillance Epidemiology and End Results SEER Program. SEER*Stat Database: Incidence-SEER 13 Regs Public-Use, November 2004 Sub (1973-2002 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission. [Accessed 20 Aug 2011.] Available from URL http://www.seer.cancer. gov
14. Asamura H, Goya T, Koshiishi Y, et al,. How should the TNM staging system for lung cancer be revised? A simulation based on the Japanese Lung Cancer Registry populations. J. Thorac. Cardiovasc. Surg. 2006; 132: 316-19. (Pubitemid 44092848)
15. Rami-Porta R, Wittekind C, Goldstraw P,. Complete resection in lung cancer surgery: proposed definition. Lung Cancer 2005; 49: 25-33. (Pubitemid 40798090)
16. Kawase A, Yoshida J, Ishii G, et al,. Visceral pleural invasion classification in non-small cell lung cancer. J. Thora. Oncol. 2010; 5: 1784-8.
17. Ou SH, Zell JA, Ziogas A, et al,. Prognostic significance of the non-size-based AJCC T2 descriptors: visceral pleura invasion, hilar atelectasis, or obstructive pneumonitis in stage IB non-small cell lung cancer is dependent on tumor size. Chest 2008; 133: 662-9. (Pubitemid 351367374)
18. Sakakura N, Mori S, Okuda K, et al,. Subcategorization of lung cancer based on tumor size and degree of visceral pleural invasion. Ann. Thorac. Surg. 2008; 86: 1084-90.
19. Shim HS, Park IK, Lee CY, et al,. Prognostic significance of visceral pleural invasion in the forthcoming (seventh) edition of TNM classification for lung cancer. Lung Cancer 2009; 65: 161-5.
20. Shimizu K, Yoshida J, Nagai K, et al,. Visceral pleural invasion classification in non-small cell lung cancer: a proposal on the basis of outcome assessment. J. Thorac. Cardiovasc. Surg. 2004; 127: 1574-8. (Pubitemid 38725433)
21. Yoshida J, Nagai K, Asamura H, et al,. Visceral pleura invasion impact on non-small cell lung cancer patient survival: its implications for the forthcoming TNM staging based on a large-scale nation-wide database. J. Thora. Oncol. 2009; 4: 959-63.
22. Saito Y, Yamakawa Y, Kiriyama M, et al,. Evaluation of new TNM lung cancer classification. Jpn. J. Thorac. Cardiovasc. Surg. 2000; 48: 499-505.
23. Sakakura N, Mori S, Ishiguro F, et al,. Subcategorization of resectable non-small cell lung cancer involving neighboring structures. Ann. Thorac. Surg. 2008; 86: 1076-83.
24. Ou SH, Zell JA, Ziogas A, et al,. Prognostic factors for survival of stage I nonsmall cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer 2007; 110: 1532-41. (Pubitemid 47463068)
25. Dediu M, Crisan E, Radut M, et al,. The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational study. Lung Cancer 2009; 63: 271-6.
26. William WNJ, Lin HY, Lee JJ, et al,. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the Surveillance, Epidemiology, and End Results data. Chest 2009; 136: 701-9.
27. Ou SH, Zell JA,. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry. J. Thora. Oncol. 2008; 3: 216-27. (Pubitemid 351654320)
28. Ruffini E, Filosso PL, Bruna MC, et al,. Recommended changes for T and N descriptors proposed by the International Association for the Study of Lung Cancer-Lung Cancer Staging Project: a validation study from a single-centre experience. Eur. J. Cardiothorac. Surg. 2009; 36: 1037-44.
29. Suzuki M, Yoshida S, Tamura H, et al,. Applicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers. Eur. J. Cardiothorac. Surg. 2009; 36: 1031-6.
30. Kameyama K, Takahashi M, Ohata K, et al,. Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution. J. Thorac. Cardiovasc. Surg. 2009; 137: 1180-84.
31. Lyons G, Quadrelli S, Jordan P, et al,. Clinical impact of the use of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers. Lung Cancer 2011; 74: 244-7.
32. Ji H, Bai H, Han B,. [Analysis of subclassification by size and survival-associated factors of stage I non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi [Chin J Lung Cancer] 2009; 12: 989-94.
33. Li Z, Yu Y, Lu J, et al,. Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China. J. Thora. Oncol. 2009; 4: 702-9.
34. Ye C, Masterman JR, Huberman MS, et al,. Subdivision of the T1 size descriptor for stage I non-small cell lung cancer has prognostic value: a single institution experience. Chest 2009; 136: 710-15.
35. Raj JV, Coulden R, Entwisle J,. IASLC Lung Cancer Staging Project-a radiologist perspective. J. Thora. Oncol. 2008; 3: 318-19. Author reply 319-20. (Pubitemid 351654336)
36. The Japan Lung Cancer Society. Classification of Lung Cancer, 1st English edn. Kanehara & Co, Tokyo, 2000.
37. Mountain C, Dresler C,. Regional lymph node classification for lung cancer staging. Chest 1997; 111: 1718-23. (Pubitemid 27260108)
38. Rusch VW, Asamura H, Watanabe H, et al,. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J. Thora. Oncol. 2009; 4: 568-77.
39. Lee JG, Lee CY, Bae MK, et al,. Validity of International Association for the Study Of Lung Cancer proposals for the revision of N descriptors in lung cancer. J. Thora. Oncol. 2008; 3: 1421-6.
40. Rena O, Massera F, Robustellini M, et al,. Use of the proposals of the international association for the study of lung cancer in the forthcoming edition of lung cancer staging system to predict long-term prognosis of operated patients. Cancer J. 2010; 16: 176-81.
41. Takamochi K, Oh S, Suzuki K,. Prognostic evaluation of nodal staging based on the new IASLC lymph node map for lung cancer. Thorac. Cardiovasc. Surg. 2010; 58: 345 -9.
42. Demir A, Turna A, Kocaturk C, et al,. Prognostic significance of surgical-pathologic N1 lymph node involvement in non-small cell lung cancer. Ann. Thorac. Surg. 2009; 87: 1014-22.
43. Kim MS, Lee HS, Lee JM, et al,. Prognostic value of single nodal zone metastasis in non-small-cell lung cancer. Eur. J. Cardiothorac. Surg. 2010; 38: 491-7.
44. Klikovits T, End A, Riedl G, et al,. Effects of reclassification from the TNM-6 into the TNM-7 staging system in bronchoplastic resection for non-small cell lung cancer. Interact. Cardiovasc. and Thorac. Surg. 2011; 13: 29-34.
45. Chien CR, Yang ST, Chen CY, et al,. Impact of the new lung cancer staging system for a predominantly advanced-disease patient population. J. Thora. Oncol. 2010; 5: 340-43.
46. Strand TE, Rostad H, Wentzel-Larsen T, et al,. A population-based evaluation of the seventh edition of the TNM system for lung cancer. Eur. Respir. J. 2010; 36: 401-7.
47. Fukui T, Mori S, Hatooka S, et al,. Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non-small cell lung cancers. J. Thorac. Cardiovasc. Surg. 2008; 136: 1343-8.
48. Stahel RA, Ginsberg R, Havemann K, et al,. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1989; 5 (4-6): 119-26. (Pubitemid 20053516)
49. Ou SH, Zell JA,. The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition. J. Thora. Oncol. 2009; 4: 300-10.
50. Mezzetti M, Raveglia F, Panigalli T, et al,. Assessment of outcomes in typical and atypical carcinoids according to latest WHO classification. Ann. Thorac. Surg. 2003; 76: 1838-42. (Pubitemid 37510488)
51. Travis WD, Giroux DJ, Chansky K, et al,. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J. Thora. Oncol. 2008; 3: 1213-23.
52. Lim E, Goldstraw P, Nicholson AG, et al,. Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J. Thora. Oncol. 2008; 3: 1194-201.
53. Cao C, Yan TD, Kennedy C, et al,. Bronchopulmonary carcinoid tumors: long-term outcomes after resection. Ann. Thorac. Surg. 2011; 91: 339-43.
54. Skov BG, Krasnik M, Lantuejoul S, et al,. Reclassification of neuroendocrine tumors improves the separation of carcinoids and the prediction of survival. J. Thora. Oncol. 2008; 3: 1410-15.
55. Sculier J-P, Chansky K, Crowley JJ, et al,. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J. Thora. Oncol. 2008; 3: 457-66. (Pubitemid 351630271)
56. Paesmans M, Berghmans T, Dusart M, et al,. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J. Thora. Oncol. 2010; 5: 612-19.
57. Mok TS, Wu Y-L, Thongprasert S, et al,. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361: 947-57.
58. Sriram KB, Larsen JE, Yang IA, et al,. Genomic medicine in non-small cell lung cancer: paving the path to personalized care. Respirology 2011; 16: 257-63.
59. Sriram KB, Tan ME, Savarimuthu SM, et al,. Screening for activating EGFR mutations in surgically resected non-small cell lung cancer. Eur. Respir. J. 2011; 38: 903-10.
60. Giroux DJ, Rami-Porta R, Chansky K, et al,. The IASLC Lung Cancer Staging Project: data elements for the prospective project. J. Thora. Oncol. 2009; 4: 679-83.